UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: A new generation of anti-cancer agents for the new century?

Anti-Cancer Drug Design

Volumn 15, Issue 1, 2000, Pages 43-52

  Akinaga, Shiro ^a   Sugiyama, Kazuyo ^a   Akiyama, Tadakazu ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Apoptosis; Cell cycle checkpoint; Indolocarbazole; Protein kinase; Topoisomerase; UCN 01

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CARBAZOLE DERIVATIVE; CEP 751; MIDOSTAURIN; PROTEIN KINASE INHIBITOR; REBECCAMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; PRIORITY JOURNAL; REVIEW;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; DNA DAMAGE; ENZYME INHIBITORS; HUMANS; STAUROSPORINE;

STREPTOMYCES SP.;

EID: 0034040974     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Abe K., Yoshida M., Usui T., Horiuchi S., Beppu T. (1991) Highly synchronous culture of fibroblasts from G2 block caused by staurosporine, a potent inhibitor of protein kinases. Experimental Cell Research, 192, 122.
2. Akinaga S., Gomi K., Morimoto M., Tamaoki T., Okabe M. (1991) Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Research, 51, 4888.
3. Akinaga S., Nomura K., Gomi K., Okabe M. (1992) Synergistic antitumor effect of UCN-01, a protein kinase C inhibitor, combined with various anti-cancer agents. Proceedings of the American Association for Cancer Research, 33, 514.
4. Akinaga S., Nomura K., Gomi K., Okabe M. (1993a) Diverse effects of indolocarbazole compounds on the cell cycle progression of ras-transformed rat fibroblast cells. Journal of Antibiotics, 46, 1767.
5. Akinaga S., Nomura K., Gomi K., Okabe M. (1993b) Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemotherapy and Pharmacology, 32, 183.
6. Akinaga S., Nomura K., Gomi K., Okabe M. (1994) Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemotherapy and Pharmacology, 33, 273.
7. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdil in p53-mutated human epidermoid carcinoma A431 cells. Cancer Research, 57, 1495.
8. 1 regulation in A431 cells synchronized at M phase by nocodazole. Anti-Cancer Drugs, 10, 67.
9. 1 phase accumulation. Japanese Journal of Cancer Research, 90, 1364.
10. Arakawa H., Iguchi T., Morita M., Yoshinari T., Kojiri K., Suda H., Okura A., Nishimura S. (1995) Novel indolocarbazole compound 6-N-formylamino-12, 13-dihydro-1, 11-dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c] carbazole-5,7(6H)-dione (NB-506): its potent antitumor activities in mice. Cancer Research, 55, 1316.
11. Beltran P.J., Fan D., Fidler I.J., O'Brian C.A. (1997) Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. Biochemical Pharmacology, 53, 245.
12. Bertrand R., Solary E., O'Connor P., Kohn K.W., Pommier Y. (1994) Induction of a common pathway of apoptosis by staurosporine. Experimental Cell Research, 211, 314.
13. Bredel M., Pollack I.F., Freund J.M., Rusnak J., Lazo J.S. (1999) Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion. Journal of Neuro-Oncology, 41, 9.
14. Bruno S., Ardelt B., Skierski J.S., Traganos F., Darzynkiewicz Z. (1992) Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Research, 51, 470.
15. Bunch R.T., Eastman A. (1996) Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clinical Cancer Research, 2, 791.
16. Bunch R.T., Eastman A. (1997) 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S phase arrest in Chinese hamster ovary cells. Cell Growth and Differentiation, 8, 779.
17. Camoratto A.M., Jani J.P., Angeles T.S., Maroney A.C., Sanders C.Y., Murakata C., Neff N.T., Vaught J.L., Issacs J.T., Dionne C. (1997) CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity. International Journal of Cancer, 72, 673.
18. Chen Y.N.P., Sharma S.K., Ramsey T.M., Jiang L., Martin M.S., Baker K., Adams P.D., Bair K.W., Kaelin W.G. (1999) Selective killing of transformed cells by cyclin/ cyclin-dependent kinase 2 antagonists. Proceedings of the National Academy of Sciences, USA, 96, 4325.
19. Courage C., Bradder S.M., Jones T., Schultze-Mosgau M.H., Gescher A. (1997) Characterisation of novel human lung carcinoma cell lines selected for resistance to antineoplastic analogues of staurosporine. International Journal of Cancer, 73, 763.
20. Crissman H.A., Gadbois D.M., Tobey R.A., Bradbury E.M. (1991) Transformed mammalian cells are deficient in kinase-mediated control of progression through the G1 phase of the cell cycle. Proceedings of the National Academy of Sciences, USA, 88, 7580.
21. Datto M.B., Li Y., Panus J.F., Howe D.J., Xiong Y., Wang X.F. (1995) Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proceedings of the National Academy of Sciences, USA, 92, 5545.
22. Dionne C., Camoratto A.M., Jani J.P., Emerson E., Neff N., Murakata C., Djakiew D., Lamb J., Bova S., George D., Issacs J.T. (1998) Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clinical Cancer Reasearch, 4, 1887.
23. Dowlati A., Remick S.C., Majka S., Ingalls S., Hoppel C., Spiro T., Gerson S., Willson K.V. (1999) A phase 1 and pharmacokinetic study of rebeccamycin analog (NSC-655649) given five daily for 5 consecutive days. Proceedings of the American Society of Clinical Oncology, 18, 694.
24. Fan S., Smith M.L., Rivet D.J. II, Duba D., Zhan Q., Kohn K.W., Fornace A.J. Jr, O'Connor P.M. (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Research, 55, 1649.
25. Fukuda M., Nishio K., Kanazawa F., Ogasawara H., Ishida T., Arioka H., Bojanowski K., Oka M., Saijo N. (1996) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung carcinoma cells. Cancer Research, 56, 789.
26. Fuse E., Tanii H., Kurata N., Kobayashi H., Shimada Y., Tamura T., Sasaki Y., Tanigawara Y., Lush R.D., Headlee D., Figg WD., Arbuck S.G., Senderowicz A.M., Sausville E.A., Akinaga S., Kuwabara T., Kobayashi S. (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α 1-acid glycoprotein. Cancer Research, 58, 3248.
27. George D.J., Dionne C.A., Jani J., Angeles T., Murakata C., Lamb J., Issacs J.T. (1999) Sustained in vivo regression of Dunning H rat prostate cancers treated with combination of androgen ablation and trk tyrosine kinase inhibitors, CEP-751 (KT6587) or CEP-701 (KT5555). Cancer Research, 59, 2395.
28. Gescher A. (1998) Analogs of staurosporine: potential anticancer drugs? General Pharmacology, 31, 721.
29. Graves P.R., Yu L., Schwarz J.K., Gales J., Sausville E.A., O'Connor P.M., Piwnica-Worms H. (2000) The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. Journal of Biological Chemistry, 275, 5600.
30. Hakem A., Sasaki T., Kozieradzki I., Penninger J.M. (1999) The cyclin-dependent kinase Cdk2 regulates thymocyte apoptosis. Journal of Experimental Medicine, 189, 957.
31. Harkin S.T., Cohen G.M., Gescher A. (1998) Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C. Molecular Pharmacology, 54, 663.
32. Hsueh C.T., Kelsen D., Schwartz G.K. (1998) UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clinical Cancer Research, 4, 2201.
33. Husain A., Yan X.J., Rosales N., Aghajanian C., Schwartz O.K., Spriggs D.R. (1997) UCN-01 in ovary cancer cells: Effective as a single agent and in combination with cisdiamminedichloroplatinum(II) independent of p53 status. Clinical Cancer Research, 3, 2089.
34. Ikegami Y., Yano S., Nakano K. (1996) Effects of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells. Arzneimittel-Forschung/Drug Research, 46, 201.
35. Johnson D.G., Walker C. L. (1999) Cyclins and cell cycle checkpoints. Annual Review of Pharmacology and Toxicology, 39, 295.
36. Kawakami K., Futami H., Takahara J., Yamaguchi K. (1996) UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochemical and Biophysical Research Communications, 219, 778.
37. Kurata N., Kuwabara T., Tanii H., Fuse E. Akiyama T., Akinaga S., Kobayashi H., Yamaguchi K., Kobayashi S. (1999) Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. Cancer Chemotherapy and Pharmacology, 44, 12.
38. McDonald A.C., Propper D., King D., Champain K., Graf P., Man A., Caponigro F., Thavasu P., Balkwill F., Twelves C., Kaye S.B. (1997) Phase 1 and pharmacokinetic study of CGP 41251, an inhibitor of protein kinase C. Proceedings of the American Society of Clinical Oncology, 16, 742.
39. Mehta A.B., Virchis A.E., Jones D.T., Hart S.M., Wickremasinghe R.G., Prentice H.G., Young K.L., Man A., Csermak-Renner K., Ganeshaguru K. (1997) Preliminary results of a phase 2 study on a protein kinase C inhibitor (CGP 41251) in low grade lymphoproliferative disorders. Blood, 90 (Supplement 1), 3463.
40. Meikrantz W., Gisselbrecht S., Tam S.W., Schlegel R. (1994) Activation of cyclin A-dependent protein kinases during apoptosis. Proceedings of the National Academy of Sciences, USA, 91, 3754.
41. Meyer T., Regenass U., Fabbro D., Alteri E., Rosel J., Muller M., Caravatti G., Matter A. (1989) A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. International Journal of Cancer, 43, 851.
42. Mizuno K., Noda K., Ueda Y., Hanaki H., Saido T.C., Ikuta T., Kuroki T., Tamaoki T., Hirai S., Osada S., Ohono S. (1995) UCN-01, an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily. FEBS Letters, 359, 259.
43. Monks M., Vaigro-Wolff A., Hose C., Sausville E.A., O'Connor P.M. (1997) Synergistic interactions between UCN-01 and various anti-cancer agents in vitro: relationship to p53 function. Proceedings of the American Association for Cancer Research, 38, 322.
44. Nieves-Neira W, Pommier Y. (1999) Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathway. International Journal of Cancer, 82, 396.
45. Nishio K., Fukumoto H., Iwamoto Y., Fukuoka K., Usuda J., Naruse I., Suzuki T., Sunami T., Kuh H.J., Tamura T., Saijo N. (1998) Expression of Fas and Fas-ligand in activation-induced apoptotic lymphocytes treated with UCN-01. Proceedings of the American Association for Cancer Research, 39, 92.
46. Park D.S., Levine B., Ferrari G, Greene L.A. (1997) Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-derived sympathetic neurons. Journal of Neuroscience, 17, 8975.
47. Pollack I.F., Kawecki S., Lazo J.S. (1996) Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. Journal of Neurosurgery, 84, 1024.
48. (+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Research, 55, 1643.
49. Russell P. (1998) Checkpoints on the road to mitosis. Trends in Biochemical Sciences, 23, 399.
50. Sarkana J.N., Busby E.C., Tibbetts R.S., Roos P., Taya Y., Karnitz L.M., Abraham R.T. (1999) Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Research, 59, 4375.
51. Sedlak J., Hunakova L., Duraj J., Chorvath B., Novotny L. (1995) Effects of protein kinase C inhibitor, staurosporine derivative CGP 41251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines. Anti-Cancer Drugs, 6, 70.
52. Sedlak J., Hunakova L., Sulikova M., Chorvath B. (1997) Protein kinase inhibitor-induced alterations of drug uptake, cell cycle and surface antigen expression in human multidrug-resistant (PgP and MRP) promyelocytic leukemia HL-60 cells. Leukemia Research, 21, 449.
53. Senderowicz A.M., Headlee D., Lush R.M., Arbuck S., Bauer K., Figg W.D., Murgo A. Inoue K., Kobayashi S., Kuwabara T., Sausville E.A. (1999) Phasetrial of infusional UCN-01, a protein kinase inhibitor, in patients with refractory neoplasms. Proceedings of the American Society of Clinical Oncology, 18, 612.
54. Seynaeve C.M., Stetler-Stevenson M., Sebers S., Kaur G., Sausville E.A., Worland P.J. (1993) Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Research, 53, 2081.
55. Seynaeve C.M., Kazanietz M.G., Blumberg P.M., Sausville E.A., Worland P.J. (1994) Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Molecular Pharmacology, 45, 1207.
56. Shao R.G., Cao C.X., Pommier Y. (1997a) Activation of PKCa downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL-60 cells. Journal of Biological Chemistry, 272, 31321.
57. Shao R.G., Cao C.X., Shimizu T., O'Connor P.M., Kohn K.W., Pommier Y. (1997b) Abrogation of an S phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Research, 57, 4029.
58. Shao R.G., Shimizu T., Pommier Y. (1997e) 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53. Experimental Cell Research, 234, 388.
59. Shao R.G., Cao C.X., Zhang H., Kohn K.W., Wold M.S., Pommier Y. (1999) Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO Journal, 18, 1397.
60. cdc2 activation required for apoptosis. Science, 263, 1143.
61. Shi Z., Plunkett W. (1999) Induction of apoptosis without cell cycle progression by UCN-01 abrogates gemcitabine induced S phase arrest in human myeloid ML-1 cells. Proceedings of the American Association for Cancer Research, 40, 305.
62. Shibata Y., Nishimura S., Okuyama A., Nakamura T. (1996) p53-independent induction of apoptosis by cyclin-dependent kinase inhibition. Cell Growth and Differentiation, 7, 887.
63. 1 checkpoint function as determinants of resistance of human lung cancer cells against antisignaling drug UCN-01 (7-hydroxystaurosporine). Cancer Research, 59, 4406.
64. 2 checkpoint abrogation. International Journal of Cancer, 85, 703.
65. Takahashi I., Kobayashi E., Asano K., Yoshida M., Nakano H. (1987) UCN-01, a selective inhibitor of protein kinase C from Streptomyces. Journal of Antibiotics, 40, 1782.
66. Takahashi I., Kobayashi E., Nakano H., Murakata C., Saitoh H., Suzuki K., Tamaoki T. (1990) Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C. Journal of Pharmacology and Experimental Therapeutics, 255, 1218.
67. Tamura T., Sasaki Y., Minami H., Fujii H., Ito K., Igarashi T., Kamiya T., Ohtsu T., Onozawa Y., Yamamoto N., Yamamoto N., Watanabe Y., Tanigawara Y., Fuse E., Kuwabara T., Kobayashi S., Shimada Y. (1999) Phase study of UCN-01 by 3-hour infusion. Proceedings of the American Society of Clinical Oncology, 18, 611.
68. Usui T., Yoshida M., Abe K., Osada H., Isono K., Beppu T. (1991) Uncoupled cell cycle without mitosis induced by a protein kinase inhibitor, K-252a. Journal of Cell Biology, 115, 1275.
69. Utz I., Spitaler M., Rybczynska M., Ludescher C., Hilbe W., Regenass U., Grunicke H., Hoffmann J. (1998) Reversal of mutidrug resistance by the staurosporine derivative CGP 41251 and CGP 42700. International Journal of Cancer, 77, 64.
70. Wang Q., Worland P.J., Clark J.L., Carlson B.A., Sausville E.A. (1995) Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth and Differentiation, 6, 927.
71. Wang Q., Fan S., Eastman A., Worland P.J., Sausville E.A., O'Connor P.M. (1996) UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. Journal of the National Cancer Institute, 88, 956.
72. Wang S., Vrana J.A., Bartimole T.M., Freemerman A.J., Jarvis W.D., Kramer L.B., Krystal G., Dent P., Grant S. (1997) Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-β-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress bcl-2. Molecular Pharmacology, 52, 1000.
73. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornace A.J. Jr, Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., Van Osdol W.W., Monks A.P., Scudiero D.A., Sausville E.A., Zaharevitz D.W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E., Paull K.D. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science, 275, 343.
74. Yamashita Y., Fujii N., Murakata C., Ashizawa T., Okabe M., Nakano H. (1992) Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry, 31, 12069.
75. Yoshinari T., Matsumoto M., Arakawa H., Okada H., Noguchi K., Suda H., Okura A., Nishimura S. (1995) Novel antitumor indolocarbazole compound 6-N-formylamino-12, 13-dihydro-1, 11-dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2, 3-a]pyrrolo[3, 4-c]carbazole-5,7-(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Research, 55, 1310.
76. 2 arrest through a cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the cdc25C phosphatase. Journal of Biological Chemistry, 273, 33455.